One year ago, we announced that our company had become the sole provider of venom immunotherapy products in the U.S.—a position brought about by the departure from the market of the only other supplier. In the ensuing year, we have committed all of our resources to ensuring a long-term, consistent supply of venom products for our customers. We’re pleased to share with you this brief overview of what we’ve been working on, and advances CMS has made with reimbursements.
WARNING Important Safety Information
Intended for use only by licensed health care provider experienced in administering allergenic extracts and trained to provide immediate emergency treatment in the event of a life-threatening reaction. Observe patients for at least 30 minutes following administration. Immunotherapy may not be suitable for patients with medical conditions that reduce their ability to withstand a systemic reaction. Allergenic extracts can cause serious systemic reactions, including anaphylactic shock and in rare cases death, especially in patients who have severe or steroid-dependent asthma, cardiovascular disease, or in patients who use beta blockers. Do not inject intravenously. This product is intended for subcutaneous injection for immunotherapy and percutaneous use for diagnosis. Refer to contraindications, warnings, precautions, adverse reaction and over dosage for more detailed information.
Adverse reactions on our products can be reported by calling 800-495-7437, or by emailing firstname.lastname@example.org. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 800-FDA-1088.
For full prescribing information see our package inserts here